Effects of sulpiride induced hyperprolactinaemia in patients with Turner's syndrome.
In order to evaluate the interference of prolactin (PRL) on some aspects of pituitary-gonadal derangement observed in patients with hyperprolactinaemic amenorrhoea (HA), a GnRH stimulation test (100 micrograms i.v.) was performed on twenty-one patients with hyperprolactinaemia without evidence of pituitary tumour and in nine subjects with Turner's syndrome (TS) before and after sulpiride administration (200 mg/day orally, for 3 months). In patients with HA an enhanced response of gonadotrophins to GnRH was observed. In patients with TS a further increase of the gonadotrophin hyper-responsiveness to the releasing hormone occurred when hyperprolactinaemia was induced by chronic sulpiride administration. Since, in these patients, appreciable ovarian steroidogenesis is lacking, a direct effect of the increased plasma PRL at the hypothalamo-pituitary level is likely. In hyperprolactinaemic amenorrhoea pituitary hyper-responsiveness may not be due to PRL effects on ovarian steroidogenesis.
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010906:Pituitary Hormone-Releasing Hormones; D011388:Prolactin / Q000097:blood*; D013469:Sulpiride / Q000627:therapeutic use*; D014424:Turner Syndrome / Q000097:blood* / Q000188:drug therapy
D010906:Pituitary Hormone-Releasing Hormones; D004958:Estradiol; D013469:Sulpiride; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone